Services
FUNDRAISING
M&A
LICENSING
STRATEGIC CONSULTING
Transactions
Team
News
Contact
acticor
Acticor Biotech announces the enrollment of the first US patient in its Phase 2/3 study ACTISAVE for the treatment of stroke
Show more
Acticor Biotech obtains “PRIME” status from the European Medicines Agency for glenzocimab in the treatment of stroke
Show more
Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies
Show more
Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022
Show more
Acticor Biotech announces its 2021 full-year financial results and gives an update on its clinical development
Show more
Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)
Show more